Deregulated WNT signaling has been shown to favor malignant transformation, tumor progression, and resistance to conventional cancer therapy in a variety of preclinical and clinical settings. Accumulating evidence suggests that aberrant WNT signaling may also subvert cancer immunosurveillance, hence promoting immunoevasion and resistance to multiple immunotherapeutics, including immune checkpoint blockers. Here, we discuss the molecular and cellular mechanisms through which WNT signaling influences cancer immunosurveillance and present potential therapeutic avenues to harness currently available WNT modulators for cancer immunotherapy.
CITATION STYLE
Galluzzi, L., Spranger, S., Fuchs, E., & López-Soto, A. (2019, January 1). WNT Signaling in Cancer Immunosurveillance. Trends in Cell Biology. Elsevier Ltd. https://doi.org/10.1016/j.tcb.2018.08.005
Mendeley helps you to discover research relevant for your work.